Here, sensitivity of myeloma cells with or without del(8)(p21) to bortezomib and soluble TRAIL/APO2L is assessed in order to evaluate the impact of differential gene expression driven by 8p21 deletion, such as TRAIL-R4, on myeloma cell survival. This evidence concerns the gene TNFRSF10D and plasma cell myeloma.